Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
opens new tab on Friday said it had struck a licensing deal worth ... well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in ...
Licensing agreement includes commercializing a combined Covid-19 and flu shot Sanofi and Novavax Inc. signed a licensing agreement that includes commercializing a combined Covid-19 and flu shot.
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
(ブルームバーグ): 仏製薬大手サノフィと米バイオテクノロジー企業ノババックスは、新型コロナウイルス感染症 ...
after the COVID-19 vaccine maker struck a licensing deal with Sanofi (SASY.PA) , opens new tab. Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 ...
Novavax said the licensing agreement allows ... will co-market Novavax's Covid vaccine in most countries starting in 2025. The deal also allows Sanofi to use Novavax's Covid shot and flagship ...
Under the licensing agreement, Sanofi will pay Novavax $500 million upfront with up to $700 million in milestone payments, making the deal worth up to $1.2 billion. The agreement also gives Sanofi ...
Sanofi on Friday announced it has reached a licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop ... vaccines under the deal. Sanofi also said it would take ...
Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice with its Q1 2024 financials on the back of a licensing deal with Sanofi ...